Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized RNA Medicine for Pancreatic Cancer

12 Jan 2018

Abstract excerpt

Abstract Purpose: Since drug responses vary between patients, it is crucial to develop pre-clinical or co-clinical strategies that forecast patient response. In this study, we tested whether RNA-based therapeutics were suitable for personalized medicine by using patient-derived-organoid (PDO) and patient-derived-xenograft (PDX) models. Experimental Design: We performed microRNA (miRNA) profiling of PDX samples to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to MicroRNA in disease regulation
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29330203
DOI: 10.1158/1078-0432.ccr-17-2733

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized RNA Medicine for Pancreatic CancerPMID 29330203Read ↗

Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccinesSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Precision Medicine: IL-1RA and Pancreatic Cancer OrganoidsSemantic proximity Read ↗

Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.Semantic proximity Read ↗

Preclinical Screening of Splice-Switching Antisense Oligonucleotides in PDAC OrganoidsSemantic proximity Read ↗

MicroRNA-based Targeted Therapeutics in Pancreatic CancerSemantic proximity Read ↗

Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncologySemantic proximity Read ↗

MicroRNAs in pancreatic cancer drug resistance: mechanisms and therapeutic potentialSemantic proximity Read ↗

Unveiling the microRNA landscape in pancreatic ductal adenocarcinoma patients and cancer cell modelsSemantic proximity Read ↗

Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma PatientsSemantic proximity Read ↗

Therapeutic miR-506-3p Replacement in Pancreatic Carcinoma Leads to Multiple Effects including Autophagy, Apoptosis, Senescence, and Mitochondrial Alterations In Vitro and In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.